SEB Equities analyst Jakob Lembke initiated coverage of Xvivo Perfusion with a Buy rating and SEK 410 price target.
Published first on TheFly
SEB Equities analyst Jakob Lembke initiated coverage of Xvivo Perfusion with a Buy rating and SEK 410 price target.
Published first on TheFly